Skip to main content

Advertisement

SpringerLink
Log in

Topoisomerase IIα expression rather than gene amplification predicts responsiveness of adjuvant anthracycline-based chemotherapy in women with primary breast cancer

  • Original Paper
  • Published:
Journal of Cancer Research and Clinical Oncology Aims and scope Submit manuscript

Abstract

Introduction

Adjuvant anthracycline-based chemotherapy (AbCTX) is a standard treatment for patients with primary breast cancer. Its main target is topoisomerase IIα (TopIIa), a nuclear protein which is important for DNA replication and mitosis. We propose that the overexpression of the TopIIa protein or amplification of the TopIIa gene may be useful in predicting increased responsiveness towards AbCTX.

Methods

Tumor tissues of 118 patients who received adjuvant AbCTX were examined by immunohistochemistry (IHC) and fluorescence in situ hybridisation (FISH) for TopIIa and HER2. For IHC, the primary antibodies 485 (Dako) and NCL-TOPOIIA (Novocastra) were used. FISH analysis was performed with the SPEC HER2/CEP 17 Dual Color Probe (Zytovision) and LSI TOP 2A Spectrum Orange/CEP 17 Spectrum Green probe (Abbott). TopIIa IHC was evaluated by the immunoreactive score (IRS). FISH amplification was stated at an HER2–TopIIa/CEP 17 ratio ≥2, deletion of TopIIa at a ratio <0.8.

Results

The median age of the patient population was 50 years (range 23–77), 76 (64%) had tumors >2 cm in size, 98 (85%) were nodal positive, and 72 (66%) estrogen-receptor positive. Chemotherapy regimes consisted of epirubicin–cyclophosphamide (EC 40 pts), EC-CMF (18 pts), FAC/FEC (33 pts), anthracycline–taxane combinations (23 pts) and others (4 pts). After IHC, it was found that 19% of the tumors were positive for HER2 (3+) and the median IRS for TopIIa staining was 2 (49% positive); 28 (24%) tumors showed HER2 amplification, therefrom 20/22 (91%) within the HER2 3+ group. TopIIa gene was amplified in 17 cases (16%) and deletion was seen in 6 (5%) tumors. Of all cases with HER2 gene amplification, 14 (50%) cases of TopIIa co-amplification and one case of deletion were seen. Looking at histological parameters, TopIIa IHC correlated with nodal status (P = 0.018) and high grading (G3) (P = 0.047). After a median follow-up of 42 months (range 1–242), a significant prognostic factor for local recurrence was HER2 positivity (IHC P = 0.013 and FISH P = 0.023). Thirty-two patients developed metastasis (27%), which was correlated with HER2 FISH positivity (P = 0.024) and, as a trend, Top IIa IHC negativity (P = 0.094); 25 (21%) patients died from the disease. Negative prognostic parameters were the lack of estrogen-receptor expression (P = 0.008), lymphangiosis (P = 0.02), and TopIIa IHC negativity (P = 0.03).

Conclusion

In this cohort of patients, HER2 positivity indicated higher rates of local and distant recurrence. In contrast, TopIIa IHC positivity predicted lower risk of metastases and death, thus being a positive-predictive factor for the responsiveness to AbCTX. TopIIa gene amplification did not add predictive information. Therefore, we conclude that TopIIa protein expression might rather be the target of anthracyclines independent from gene copy number.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4
Fig. 5
Fig. 6
Fig. 7

Similar content being viewed by others

References

  • Arriola E, Rodriguez-Pinilla SM, Lambros MB, Jones RL, James M, Savage K et al (2007) Topoisomerase II alpha amplification may predict benefit from adjuvant anthracyclines in HER2 positive early breast cancer. Breast Cancer Res Treat 106(2):181–189

    Article  CAS  PubMed  Google Scholar 

  • Berry DA, Cronin KA, Plevritis SK, Fryback DG, Clarke L, Zelen M et al (2005) Effect of screening and adjuvant therapy on mortality from breast cancer. N Engl J Med 353(17):1784–1792

    Article  CAS  PubMed  Google Scholar 

  • Coombes RC, Bliss JM, Wils J, Morvan F, Espie M, Amadori D et al (1996) Adjuvant cyclophosphamide, methotrexate, and fluorouracil versus fluorouracil, epirubicin, and cyclophosphamide chemotherapy in premenopausal women with axillary node-positive operable breast cancer: results of a randomized trial. The International Collaborative Cancer Group. J Clin Oncol 14(1):35–45

    CAS  PubMed  Google Scholar 

  • Cortes F, Pastor N, Mateos S, Dominguez I (2003) Roles of DNA topoisomerases in chromosome segregation and mitosis. Mutat Res 543(1):59–66

    Article  CAS  PubMed  Google Scholar 

  • Cuadros M, Villegas R (2009) Systematic review of HER2 breast cancer testing. Appl Immunohistochem Mol Morphol 17(1):1–7

    Article  CAS  PubMed  Google Scholar 

  • De Laurentiis M, Cancello G, D’Agostino D, Giuliano M, Giordano A, Montagna E et al (2008) Taxane-based combinations as adjuvant chemotherapy of early breast cancer: a meta-analysis of randomized trials. J Clin Oncol 26(1):44–53

    Article  PubMed  CAS  Google Scholar 

  • Di Leo A, Gancberg D, Larsimont D, Tanner M, Jarvinen T, Rouas G et al (2002) HER-2 amplification and topoisomerase IIalpha gene aberrations as predictive markers in node-positive breast cancer patients randomly treated either with an anthracycline-based therapy or with cyclophosphamide, methotrexate, and 5-fluorouracil. Clin Cancer Res 8(5):1107–1116

    CAS  PubMed  Google Scholar 

  • Early Breast Cancer Trialists’ Collaborative Group (EBCTCG) (2005) Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet 365(9472):1687–1717

    Google Scholar 

  • Gennari A, Sormani MP, Pronzato P, Puntoni M, Colozza M, Pfeffer U et al (2008) HER2 status and efficacy of adjuvant anthracyclines in early breast cancer: a pooled analysis of randomized trials. J Natl Cancer Inst 100(1):14–20

    Article  CAS  PubMed  Google Scholar 

  • Harris LN, Broadwater G, Abu-Khalaf M, Cowan D, Thor AD, Budman D et al (2009) Topoisomerase II{alpha} amplification does not predict benefit from dose-intense cyclophosphamide, doxorubicin, and fluorouracil therapy in HER2-amplified early breast cancer: results of CALGB 8541/150013. J Clin Oncol 27(21):3430–3436

    Article  CAS  PubMed  Google Scholar 

  • Hicks DG, Yoder BJ, Pettay J, Swain E, Tarr S, Hartke M et al (2005) The incidence of topoisomerase II-alpha genomic alterations in adenocarcinoma of the breast and their relationship to human epidermal growth factor receptor-2 gene amplification: a fluorescence in situ hybridization study. Hum Pathol 36(4):348–356

    Article  CAS  PubMed  Google Scholar 

  • Jarvinen TA, Liu ET (2003) HER-2/neu and topoisomerase IIalpha in breast cancer. Breast Cancer Res Treat 78(3):299–311

    Article  PubMed  Google Scholar 

  • Jones RL, Swanton C, Ewer MS (2006) Anthracycline cardiotoxicity. Expert Opin Drug Saf 5(6):791–809

    Article  CAS  PubMed  Google Scholar 

  • Jones S, Holmes FA, O’Shaughnessy J, Blum JL, Vukelja SJ, McIntyre KJ et al (2009) Docetaxel with cyclophosphamide is associated with an overall survival benefit compared with doxorubicin, cyclophosphamide: 7-year follow-up of US Oncology Research Trial 9735. J Clin Oncol 27(8):1177–1183

    Article  CAS  PubMed  Google Scholar 

  • Levine MN, Pritchard KI, Bramwell VH, Shepherd LE, Tu D, Paul N (2005) Randomized trial comparing cyclophosphamide, epirubicin, and fluorouracil with cyclophosphamide, methotrexate, and fluorouracil in premenopausal women with node-positive breast cancer: update of National Cancer Institute of Canada Clinical Trials Group Trial MA5. J Clin Oncol 23(22):5166–5170

    Article  CAS  PubMed  Google Scholar 

  • Martin M, Villar A, Sole-Calvo A, Gonzalez R, Massuti B, Lizon J et al (2003) Doxorubicin in combination with fluorouracil and cyclophosphamide (i.v. FAC regimen, day 1, 21) versus methotrexate in combination with fluorouracil and cyclophosphamide (i.v. CMF regimen, day 1, 21) as adjuvant chemotherapy for operable breast cancer: a study by the GEICAM group. Ann Oncol 14(6):833–842

    Article  CAS  PubMed  Google Scholar 

  • Martin-Richard M, Munoz M, Albanell J, Colomo L, Bellet M, Rey MJ et al (2004) Serial topoisomerase II expression in primary breast cancer and response to neoadjuvant anthracycline-based chemotherapy. Oncology 66(5):388–394

    Article  CAS  PubMed  Google Scholar 

  • Nielsen KV, Ejlertsen B, Moller S, Jorgensen JT, Knoop A, Knudsen H et al (2008) The value of TOP2A gene copy number variation as a biomarker in breast cancer: update of DBCG trial 89D. Acta Oncol 47(4):725–734

    Article  CAS  PubMed  Google Scholar 

  • O’Malley FP, Chia S, Tu D, Shepherd LE, Levine MN, Bramwell VH et al (2009) Topoisomerase II alpha and responsiveness of breast cancer to adjuvant chemotherapy. J Natl Cancer Inst 101(9):644–650

    Article  PubMed  CAS  Google Scholar 

  • Orlando L, Del Curto B, Gandini S, Ghisini R, Pietri E, Torrisi R et al (2008) Topoisomerase IIalpha gene status and prediction of pathological complete remission after anthracycline-based neoadjuvant chemotherapy in endocrine non-responsive Her2/neu-positive breast cancer. Breast 17(5):506–511

    Article  PubMed  Google Scholar 

  • Pritchard KI, Shepherd LE, O’Malley FP, Andrulis IL, Tu D, Bramwell VH et al (2006) HER2 and responsiveness of breast cancer to adjuvant chemotherapy. N Engl J Med 354(20):2103–2111

    Article  CAS  PubMed  Google Scholar 

  • Remmele W, Stegner HE (1987) Recommendation for uniform definition of an immunoreactive score (IRS) for immunohistochemical estrogen receptor detection (ER-ICA) in breast cancer tissue. Pathologe 8(3):138–140

    CAS  PubMed  Google Scholar 

  • Ross JS, Fletcher JA (1998) The HER-2/neu oncogene in breast cancer: prognostic factor, predictive factor, and target for therapy. Stem Cells 16(6):413–428

    Article  CAS  PubMed  Google Scholar 

  • Ryberg M, Nielsen D, Cortese G, Nielsen G, Skovsgaard T, Andersen PK (2008) New insight into epirubicin cardiac toxicity: competing risks analysis of 1097 breast cancer patients. J Natl Cancer Inst 100(15):1058–1067

    Article  CAS  PubMed  Google Scholar 

  • Schindlbeck C, Kampik T, Janni W, Rack B, Jeschke U, Krajewski S et al (2005) Prognostic relevance of disseminated tumor cells in the bone marrow and biological factors of 265 primary breast carcinomas. Breast Cancer Res 7(6):R1174–R1185

    Article  PubMed  Google Scholar 

  • Slamon DJ, Press MF (2009) Alterations in the TOP2A and HER2 genes: association with adjuvant anthracycline sensitivity in human breast cancers. J Natl Cancer Inst 101(9):615–618

    Article  CAS  PubMed  Google Scholar 

  • Tanner M, Isola J, Wiklund T, Erikstein B, Kellokumpu-Lehtinen P, Malmstrom P et al (2006) Topoisomerase IIalpha gene amplification predicts favorable treatment response to tailored, dose-escalated anthracycline-based adjuvant chemotherapy in HER-2/neu-amplified breast cancer: Scandinavian Breast Group Trial 9401. J Clin Oncol 24(16):2428–2436

    Article  CAS  PubMed  Google Scholar 

  • Tinari N, Lattanzio R, Natoli C, Cianchetti E, Angelucci D, Ricevuto E et al (2006) Changes of topoisomerase IIalpha expression in breast tumors after neoadjuvant chemotherapy predicts relapse-free survival. Clin Cancer Res 12(5):1501–1506

    Article  CAS  PubMed  Google Scholar 

  • Tubbs R, Barlow WE, Budd GT, Swain E, Porter P, Gown A et al (2009) Outcome of patients with early-stage breast cancer treated with doxorubicin-based adjuvant chemotherapy as a function of HER2 and TOP2A status. J Clin Oncol 27(24):3881–3886

    Article  CAS  PubMed  Google Scholar 

  • Vici P, Viola G, Botti C, Rossi S, Vitucci C, Corsetti S et al (2008) Docetaxel in the adjuvant therapy of HER-2 positive breast cancer patients. Clin Ter 159(6):449–452

    CAS  PubMed  Google Scholar 

  • Wang JC (2002) Cellular roles of DNA topoisomerases: a molecular perspective. Natl Rev Mol Cell Biol 3(6):430–440

    Article  CAS  Google Scholar 

Download references

Acknowledgment

This study was supported by Roche Diagnostics, Penzberg, Germany

Author information

Authors and Affiliations

  1. Department of Obstetrics and Gynecology, Campus Innenstadt, Ludwig-Maximilians-University, Maistrasse 11, 80337, Munich, Germany

    Christian Schindlbeck, C. Olivier, B. Rack, V. Engelstaedter, J. Jueckstock, C. Jenderek, U. Andergassen, U. Jeschke & K. Friese

  2. Institute of Pathology, Ludwig-Maximilians-University, Thalkirchnerstrasse 36, 80337, Munich, Germany

    D. Mayr

Authors
  1. Christian Schindlbeck
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. D. Mayr
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. C. Olivier
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. B. Rack
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. V. Engelstaedter
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. J. Jueckstock
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. C. Jenderek
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. U. Andergassen
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. U. Jeschke
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. K. Friese
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Christian Schindlbeck.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Schindlbeck, C., Mayr, D., Olivier, C. et al. Topoisomerase IIα expression rather than gene amplification predicts responsiveness of adjuvant anthracycline-based chemotherapy in women with primary breast cancer. J Cancer Res Clin Oncol 136, 1029–1037 (2010). https://doi.org/10.1007/s00432-009-0748-4

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00432-009-0748-4

Keywords

Search

Navigation